Closing the global cancer divide- performance of breast cancer care services in a middle income developing country

BMC Cancer

Teck O Lim³  Ibrahim A Wahid⁶  Kin W Leong⁵  Chiao M Lim⁹  Kananathan Ratnavelu⁹  Kean F Ho⁷  Ahmad K Mohamed¹  Matin M Abdullah¹  Jayendran Dharmaratnam⁴  Kwang J Chong⁴  Nur A Taib⁸  Cheng H Yip⁸  Lye M Tho⁸  Gwo F Ho⁸  Fuad Ismail²  Soon K Cheah²  Emran N Aina²  Gerard CC Lim² 

[1]Sime Darby Medical Centre, Petaling Jaya, Malaysia

[2]Kuala Lumpur Hospital, Kuala Lumpur, Malaysia

[3]ClinResearch SB, Kuala Lumpur, Malaysia

[4]Mahkota Cancer Centre, Melaka, Malaysia

[5]Gleneagles Medical Centre Pinang, Pinang, Malaysia

[6]Beacon International Specialist Centre, Petaling Jaya, Malaysia

[7]Mount Miriam Cancer Hospital, Pulau Pinang, Malaysia

[8]Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia

[9]Nilai Medical Centre, Nilai, Malaysia

关键词: Health system research;    Health services research;    Health policy;    Healthcare quality;    Performance measurement;    Developing country;    Cancer burden;    Breast cancer;   

Others  :  858944
DOI  :  10.1186/1471-2407-14-212

 received in 2013-07-10, accepted in 2014-03-06,  发布年份 2014

【 摘 要 】

Background

Cancer is the leading cause of deaths in the world. A widening disparity in cancer burden has emerged between high income and low-middle income countries. Closing this cancer divide is an ethical imperative but there is a dearth of data on cancer services from developing countries.

Methods

This was a multi-center, retrospective observational cohort study which enrolled women with breast cancer (BC) attending 8 participating cancer centers in Malaysia in 2011. All patients were followed up for 12 months from diagnosis to determine their access to therapies. We assess care performance using measures developed by Quality Oncology Practice Initiative, American Society of Clinical Oncology/National Comprehensive Cancer Network, American College of Surgeons’ National Accreditation Program for Breast Centers as well as our local guideline.

Results

Seven hundred and fifty seven patients were included in the study; they represent about 20% of incident BC in Malaysia. Performance results were mixed. Late presentation was 40%. Access to diagnostic and breast surgery services were timely; the interval from presentation to tissue diagnosis was short (median = 9 days), and all who needed surgery could receive it with only a short wait (median = 11 days). Performance of radiation, chemo and hormonal therapy services showed that about 75 to 80% of patients could access these treatments timely, and those who could not were because they sought alternative treatment or they refused treatment. Access to Trastuzumab was limited to only 19% of eligible patients.

Conclusions

These performance results are probably acceptable for a middle income country though far below the 95% or higher adherence rates routinely reported by centres in developed countries. High cost trastuzumab was inaccessible to this population without public funding support.

【 授权许可】

   
2014 Lim et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries: Closing the cancer divide: a blueprint to expand access to low and middle income countries. Boston, MA: Harvard Global Equity Initiative; 2011. http://ghsm.hms.harvard.edu/programs/ncd/ webcite (accessed 3 Feb 2013)
• [2]Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR: Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010, 376:1186-1193.
• [3]Boyle P, Levin B: World Cancer Report 2008. Lyon: International Agency for Research on Cancer; 2008.
• [4]Beaulieu N, Bloom D, Bloom R, Stein R: Breakaway: The Global Burden of Cancer—Challenges and Opportunities. A Report from the Economist Intelligence Unit. 2009. https://assets-livestrong-org.s3.amazonaws.com/media/site_proxy/data/c49ced3068f7205319cb1edf653dd91e0baee3ba.pdf webcite (accessed July 27, 2010)
• [5]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. Lyon: International Agency for Research on Cancer; 2010.
• [6]Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK, Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK: Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
• [7]International CT: Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic? Ann Oncol 2010, 21:680-682.
• [8]Campion FX, Larson LR, Kadlubek PJ, Earle CC, MN N: Advancing performance measurement in oncology: Quality Oncology Practice Initiative (QOPI) participation and quality outcomes. J Oncol Pract 2011, 7:31S-35S.
• [9]QOPI Quality Measures. Available at: http://qopi.asco.org/Documents/QOPISpring2012MeasuresSummary_000.pdf webcite
• [10]Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY, Stewart AK, Edge SB: American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008, 26:3631-3637.
• [11]ASCO-NCCN Quality Measures for Breast and Colorectal cancer care. Available at: http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Quality+Care/Quality+Measurement+%26+Improvement/ASCO-NCCN+Quality+Measures webcite
• [12]National Accreditation Program for Breast Centers (NAPBC): 2012 Breast Center Standards Manual. Available at: http://napbc-breast.org/ webcite
• [13]National Quality Forum. Available at: http://www.qualityforum.org/projects/ongoing/cancer/index.asp webcite
• [14]Department of Statistics, Government of Malaysia. Available at http://mysidc.statistics.gov.my/ webcite
• [15]GLOBOCAN 2012. Available at: http://globocan.iarc.fr/ webcite
• [16]Malaysia’s National Health Account Project: Health Expenditure Report 1997–2006. Kuala Lumpur: Ministry of Health Malaysia; 2008.
• [17]MOH and AMM Malaysia: Clinical Practice Guidelines: Management of Breast Cancer. 2nd edition. Kuala Lumpur: Ministry of Health Malaysia; 2010.
• [18]Devi B, Tang TS, Corbex M: Reducing by half the percentage of late presentation of breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Ann Oncol 2007, 18:1172-1176.
• [19]Hisham AN, Yip CH: Spectrum of breast cancer in Malaysian women: overview. World J Surg 2003, 27:921-993.
• [20]Cleveland clinic: Outcome Report Year 2011. Available at: http://my.clevelandclinic.org/Documents/outcomes/2011/outcomes-cancer-2011.pdf webcite
• [21]Central Vermont Medical Center (CVMC) Cancer Program Reporrt of 2011 program Activities. Available at: http://www.cvmc.org/sites/default/files/PDFs/2012-Cancer-Program-Report.pdf webcite
• [22]Maine Medical Center Cancer Institute: Breast Cancer Quality Report on Clinical Outcomes. 2011. Available at: http://www.mmc.org/workfiles/mmc_oncology/BreastCareQualityGuide_FNL.pdf webcite
• [23]Shaw Regional Cancer Center: 2012 Annual Report. Available at: http://www.shawcancercenter.com/media/219365/shaw_annual_report_2012-small.pdf webcite
• [24]Alwan MA, MacLean DR, Riley LM, d’Espaignet ET, Mathers CD, Stevens GA, Bettcher D: Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet 2010, 376:1861-1868.
• [25]Roberts I, Jackson R: Beyond disease burden: towards solution-oriented population health. Lancet 2013, 381:2219-2221.
• [26]Kulendran M, Leff DR, Kerr K, Tekkis PP, Athanasiou T, Darzi A: Global cancer burden and sustainable health development. Lancet 2013, 381:427-429.
• [27]Anderson BO, Cazap E, El Saghir NS, Yip CH, Khaled HM IV, Otero C, Adebamowo A, Badwe RA, Harford JB: Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 2011, 12:387-398.
• [28]Lee TH: Care redesign — a path forward for providers. N Engl J Med 2012, 367:5.
• [29]Porter M: What is value in health care. N Engl J Med 2010, 363:2477-2481.
• [30]Hirschler B: Insight: chasing cheaper cancer drugs. Reuters London Sun Apr 2012. Available at: http://www.reuters.com/article/2012/04/01/us-cancer-medicines-idUSBRE83005B20120401 webcite
• [31]Lim TO, Goh A, Lim YN, Zaki M, Suleiman AB: How public and private reforms dramatically improved access to dialysis therapy in Malaysia. Health Aff 2010, 29:2214-2222.